Bristol-Myers Must Face Celgene Deal Suit In NJ State Court
A New Jersey federal judge has sent back to state court class claims alleging Bristol-Myers Squibb Co. misled investors with respect to its $74 billion acquisition of Celgene Corp., dealing another...To view the full article, register now.
Already a subscriber? Click here to view full article